DigestRedComo funciona
Red
/
Empresas
Si
No verificado

Sinaptica Therapeutics, Inc.

Sobre qué escribimos

CienciaIndustriaMaterial médico sanitarioMedicina - VariosSalud

7 Comunicados de prensa

Ver todos los comunicados de prensa
18/06/2025
Biotecnología
Higiene alimentaria
Salud
Sanidad
Material médico sanitario
Ciencia
Medicina - Varios
Análisis de Mercados
Industria
Publication in Alzheimer’s & Dementia Elucidates Multimodal Mechanism of Action Underpinning Promising New Neuromodulation Therapy for Alzheimer’s
Fuente
Sinaptica Therapeutics, Inc.
Editor
Business Wire
1.00
0
02/04/2025
Industria
Biotecnología
Sanidad
Salud
Farmacéutica
Psiquiatría
Ciencia
Material médico sanitario
Medicina - Varios
Positive Data Published in Alzheimer’s Research & Therapy from 12-month Phase 2 Study in Alzheimer’s Using Personalized Neuromodulation Therapy; Trial Met All Primary and Key Secondary Endpoints
Fuente
Sinaptica Therapeutics, Inc.
Editor
Business Wire
1.00
0
20/02/2025
Industria
Tercera edad
Sanidad
Salud
Psiquiatría
Material médico sanitario
Ir de compras
Medicina - Varios
Enrollment Initiated for Phase 2 Clinical trial in Early Alzheimer’s with Sinaptica’s Second-Generation Precision Neuromodulation System
Fuente
Sinaptica Therapeutics, Inc.
Editor
Business Wire
1.00
0
15/01/2025
Mercado laboral
Industria
Ciencia
Material médico sanitario
Tercera edad
Medicina - Varios
Ir de compras
Salud
Sinaptica Announces Initiation of Co-Development of the SinaptiStim® Precision Neuromodulation System to treat Alzheimer’s Disease; On Track for Pivotal Clinical Trial Initiation in 2025
Fuente
Sinaptica Therapeutics, Inc.
Editor
Business Wire
1.00
0
31/10/2024
Eventos
Industria
Análisis de Mercados
Ciencia
Material médico sanitario
Tercera edad
Medicina - Varios
Salud
Ir de compras
Personalized Neuromodulation Treatment Significantly Slowed Alzheimer’s Progression in 12-month Phase 2 Study, Meeting Primary and Key Secondary Endpoints
Fuente
Sinaptica Therapeutics, Inc.
Editor
Business Wire
1.00
0
24/10/2024
Eventos
Industria
Ciencia
Material médico sanitario
Tercera edad
Medicina - Varios
Salud
Ir de compras
Sinaptica Therapeutics to Present Results of 52-week Phase 2 Study of Precision Neuromodulation for Alzheimer’s Diseases in Oral Presentation at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Fuente
Sinaptica Therapeutics, Inc.
Editor
Business Wire
1.00
0
09/07/2024
Análisis de Mercados
Industria
Biotecnología
Salud
Tercera edad
Farmacéutica
Ciencia
Material médico sanitario
Ir de compras
Medicina - Varios
Precision Neuromodulation Decreased Brain Atrophy and Increased Connectivity in Key Brain Network in Alzheimer’s Patients
Fuente
Sinaptica Therapeutics, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0